Table 1.
Baseline characteristics of the EVAPORATE cohort
| Total | IPE | Placebo | ||
|---|---|---|---|---|
| 68 | 31 | 37 | ||
| Mean or count (SD/%) | Mean or count (SD/%) | Mean or count (SD/%) | P | |
| Age, years | 57.4 (8.7) | 56.5 (8.9) | 58.3 (8.6) | 0.394a |
| Gender, male | 37 (54.4%) | 17 (54.8%) | 20 (54.1%) | 0.948b |
| Body mass index, kg/m2 | 33.7 (6.7) | 34.1 (6.5) | 33.3 (6.9) | 0.632a |
| Time between Visit 1 and 5 | 17.8 (3.8) | 17.2 (4.0) | 18.2 (3.6) | 0.275a |
| Ethnicity, Hispanic | 37 (54.4%) | 18 (58.1%) | 19 (51.4%) | 0.580b |
| Race, White | 56 (82.4%) | 28 (90.3%) | 28 (75.7%) | 0.565b |
| Aspirin use | 37 (54.4%) | 15 (48.4%) | 22 (59.5%) | 0.361b |
| Diabetes mellitus | 47 (69.1%) | 22 (71.0%) | 25 (67.6%) | 0.763b |
| Family history | 22 (32.4%) | 9 (29.0%) | 13 (35.1%) | 0.592b |
| Statin medication use | 68 (100.0%) | 31 (100.0%) | 37 (100.0%) | – |
| Hypertension | 52 (76.5%) | 24 (77.4%) | 28 (75.7%) | 0.866b |
| Past smoking | 29 (42.6%) | 13 (41.9%) | 16 (43.2%) | 0.986b |
a
Independent T-test.
b
Chi-square test.